Clinical Trial Update: The Efficacy of MK-8291 in Participants With Post-herpetic Neuralgia (PHN) With Allodynia (MK-8291-012) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating MK-8291 for postherpetic neuralgia has completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postherpetic Neuralgia

Drugs mentioned

• MK-8291

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Postherpetic Neuralgia | Phase 1 | Status: COMPLETED | Results posted: 2019-12-09